香港股市 已收市

Simulations Plus, Inc. (SLP)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
48.340.00 (0.00%)
收市:04:00PM EDT
48.34 0.00 (0.00%)
收市後: 04:02PM EDT

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
https://www.simulations-plus.com

版塊Healthcare
行業Health Information Services
全職員工192

高階主管

名稱頭銜支付行使價出生年份
Dr. Walter S. Woltosz M.A.S., M.S.Co-Founder & Chairman80k1945
Mr. Shawn M. O'ConnorChief Executive Officer847.56k1960
Mr. William FrederickCOO, CFO & Secretary443.12k1.29k1964
Mr. John Anthony DiBella M.S.President of PBPK & Cheminformatics Solutions399.8k2.13M1980
Dr. Brett A. Howell Ph.D.President of Quantitative Systems Pharmacology Solutions321.67k1984
Ms. Jill Fiedler-Kelly M.S.President of Clinical Pharmacology & Pharmacometrics Services393.77k17.43k1969
Ms. Viera Lukacova Ph.D.Chief Science Officer
Dr. Bud Nelson J.D., Ph.D.VP of Corporate Counsel & Personal Data Protection Officer
Ms. Arlene PadronCorporate Director of Marketing
Dr. Scott Q. SilerChief Scientific Officer of DILIsym Services, Inc
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

公司管治

截至 2024年5月1日 止,Simulations Plus, Inc. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中:2;董事會:5;股東權利:1;現金賠償:5。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。